- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00754637
Microplasty Tibial Tray Data Collection (MTT)
Microplasty Tibial Tray Multi-Center Data Collection
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
FDA has cleared this device via premarket notification 510(k) K063732. By being CE Marked, the Microplasty Tibial Tray also conforms to the essential requirements of EC Directive 93/42/EEC; in accordance to 13485:2003. The data gathered would be collated and used to provide feedback to design engineers, support marketing efforts, and answer potential questions from reimbursement agencies, and will serve as a part of Biomet's Post Market Surveillance System.
Inclusion/exclusion criteria are identical to those indications and contraindications stated in the FDA approved labeling for the device in 510(k) K063732 Surgical techniques and patient care are to be standard for the surgeon participating in the protocol and should be maintained the same throughout the course of the data-collection. There will be no experimental or investigational devices used. There will be no experimental or investigational surgical techniques used. The devices and products will be used in accordance with their instructions for use and/or approved labeling. Any use of the device or collection of clinical data outside of the United States should comply with all local, state, and/or national and international regulations.
Function will be assessed through the Knee Society Score . Survivorship will be documented by asking the surgeon to document revisions and complications.
Studientyp
Kontakte und Standorte
Studienorte
-
-
Michigan
-
Rochester Hills, Michigan, Vereinigte Staaten, 48307
- The DeClaire Knee & Orthopaedic Institute
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
The inclusion criteria will be identical to the indications stated in the FDA approved labeling for the device in 510(k) K063732. These indications are stated below:
- Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartments are involved.
- Correction of varus, valgus, or posttraumatic deformity.
- Correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure.
Patient selection factors to be considered include:
- Need to obtain pain relief and improve function
- Ability and willingness of the patient to follow instructions, including control of weight and activity level
- A good nutritional state of the patient, and
- The patient must have reached full skeletal maturity
Non-coated (Interlock®) devices are indicated for cemented application only.
Exclusion Criteria:
The exclusion criteria will be identical to the contraindications stated in the FDA approved labeling for the device in 510(k) K063732. These contraindications are stated below:
Absolute contraindications include: infection, sepsis, and osteomyelitis.
Relative contraindications include:
- Uncooperative patient or patient with neurologic disorders who are incapable of following directions,
- Osteoporosis,
- Metabolic disorders which may impair bone formation,
- Osteomalacia,
- Distant foci of infections which may spread to the implant site,
- Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram,
- Vascular insufficiency, muscular atrophy, neuromuscular disease,
- Incomplete or deficient soft tissue surrounding the knee.
Biomet Microplasty™ Tibial Trays are contraindicated for use with constrained bearings.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
---|
510(k) Inclusion Criteria
Any person meeting the inclusion criteria for the device may be included in this study.
These patients tend to be those seeking relief from painful or debilitating knee joint disease.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Score der Knee Society
Zeitfenster: 5 Jahre
|
5 Jahre
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Radiographic Data
Zeitfenster: 10 Years
|
10 Years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Ken Beres, MD, Zimmer Biomet
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Insall JN, Dorr LD, Scott RD, Scott WN. Rationale of the Knee Society clinical rating system. Clin Orthop Relat Res. 1989 Nov;(248):13-4.
- Amstutz HC, Thomas BJ, Jinnah R, Kim W, Grogan T, Yale C. Treatment of primary osteoarthritis of the hip. A comparison of total joint and surface replacement arthroplasty. J Bone Joint Surg Am. 1984 Feb;66(2):228-41.
- Brooks, et al. (Eds.). (2003) The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective. Netherlands: Kluwer Academic Publishers.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 335
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Gelenkerkrankung
-
Bispebjerg HospitalAbgeschlossen
-
Western University of Health SciencesAbgeschlossenCharcot-FußgelenkVereinigte Staaten
-
University of UtahNational Cancer Institute (NCI)RekrutierungErmüdung | Sitzende Lebensweise | Metastasierendes Prostatakarzinom | Prostatakrebs im Stadium IV AJCC (American Joint Committee on Cancer) v8 | Stadium IVA Prostatakrebs AJCC (American Joint Committee on Cancer) v8 | Prostatakrebs im Stadium IVB AJCC (American Joint Committee on Cancer) v8Vereinigte Staaten
-
Postgraduate Institute of Medical Education and...Abgeschlossen
-
Cairo UniversityAbgeschlossen
-
Rashmi Verma, MDNational Cancer Institute (NCI)RekrutierungKastrationsresistentes Prostatakarzinom | Metastasierendes Prostata-Adenokarzinom | Stadium IVB Prostatakrebs American Joint Committee on Cancer (AJCC) v8Vereinigte Staaten
-
Jonsson Comprehensive Cancer CenterNoch keine RekrutierungProstatakarzinom | Stadium IVB Prostatakrebs American Joint Committee on Cancer (AJCC) v8Vereinigte Staaten
-
Centre Hospitalier Universitaire de NīmesRekrutierungCharcot-Fußgelenk | OsteoarthropathieFrankreich
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)RekrutierungAnatomischer Brustkrebs im Stadium II AJCC v8 | Anatomischer Brustkrebs im Stadium III AJCC v8 | Brustkrebs im Frühstadium | Anatomischer Brustkrebs im Stadium I American Joint Committee on Cancer (AJCC) v8Vereinigte Staaten
-
Bispebjerg HospitalH. Lundbeck A/S; Steno Diabetes Center Copenhagen; The Danish Diabetes Association und andere MitarbeiterUnbekanntDiabetischer Fuß | Charcot-JointDänemark